- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BMY
Recent news which mentions BMY
Tickers
BMY
From Motley Fool
Insiders Selling Zoom Video Communications, Bristol-Myers Squibb And This Footwear Manufacturer
May 05, 2023
From Benzinga
7 Best Dividend Stocks to Buy Now in May 2023
May 03, 2023
From Motley Fool
From Motley Fool
From Benzinga
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
May 01, 2023
From Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 27, 2023
From Benzinga
Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down
April 27, 2023
Tickers
BMY
From Benzinga
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
April 27, 2023
From Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
April 27, 2023
From Benzinga
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
April 26, 2023
From Benzinga
From Benzinga
Bristol-Myers Squibb Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 25, 2023
Tickers
BMY
From Benzinga
From Motley Fool
From Motley Fool
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
April 24, 2023
From Benzinga
From Motley Fool
Thinking Of Buying Healthpeak Properties? Here Are The Properties And Tenants You'd Be Adding To Your Portfolio
April 21, 2023
From Benzinga
Why Shares of Legend Biotech Jumped Wednesday
April 19, 2023
From Motley Fool
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients
April 18, 2023
From Benzinga
Merck’s $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunology
April 17, 2023
From MarketWatch
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
April 16, 2023
From InvestorPlace
From Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
From Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
From Benzinga
2 Top Stocks to Buy in April and Hold Forever
April 08, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.